Obstructive sleep apnea and comorbidities: a dangerous liaison
Obstructive sleep apnea (OSA) is a highly prevalent disease, and is traditionally associated with increased cardiovascular risk. The role of comorbidities in OSA patients has emerged recently, and new conditions significantly associated with OSA are increasingly reported. A high comorbidity burden worsens prognosis, but some data suggest that CPAP might be protective especially in patients with comorbidities. Aim of this narrative review is to provide an update on recent studies, with special attention to cardiovascular and cerebrovascular comorbidities, the metabolic syndrome and type 2 diabetes, asthma, COPD and cancer. Better phenotypic characterization of OSA patients, including comorbidities, will help to provide better individualized care. The unsatisfactory adherence to CPAP in patients without daytime sleepiness should prompt clinicians to examine the overall risk profile of each patient in order to identify subjects at high risk for worse prognosis and provide the optimal treatment not only for OSA, but also for comorbidities.
KeywordsMortality prognosis cardiovascular disease diabetes asthma COPD cancer
Acute Coronary Syndromes
Body mass index
Cutaneous malignant melanoma
Chronic Obstructive Pulmonary Disease
Continuous Positive Airway Pressure
Estimated glomerular filtration rate
Forced expiratory volume in 1 s
Hypoxia Inducible Factor
Obstructive sleep apnea
Arterial partial pressure of oxygen
Arterial partial pressure of carbon dioxide
Randomized controlled trials
Sleep Disordered Breathing
Endothelial Growth Factor
Obstructive sleep apnea (OSA) is highly prevalent in the general population, and occurs at all ages . OSA is characterized by collapse of upper airways during sleep with ineffective respiratory efforts, intermittent hypoxia and sleep disruption. Continuous positive airway pressure (CPAP), mandibular advancement devices, and upper airway (UA) and maxillo-facial surgery are therapeutic options that prevent UA closure during sleep, CPAP being the gold standard for moderate-severe OSA. The typical OSA patient is overweight or obese, sleepy in passive situations or while driving, and often affected by systemic hypertension, type 2 diabetes, and dyslipidemia .
Comorbidities in OSA: the size of the problem
A recent study from Taiwan in a large number of OSA patients analyzed prevalence of comorbidities at diagnosis and their relationship with mortality risk during follow up . The study confirmed that OSA patients show a high prevalence of cardiovascular diseases (systemic hypertension, coronary artery disease, arrhythmias, ischemic stroke), respiratory diseases (COPD, asthma), and metabolic disorders (diabetes mellitus, dyslipidemia, gout). Many other disorders were also identified, including peptic ulcer disease, gastroesophageal reflux, chronic liver disease, anxiety, insomnia, and depression. The authors identified ten comorbid conditions associated with increased mortality risk, and developed a comorbidity score for OSA by taking into account the relative risk associated with each disease state and the number of comorbidities. Such an approach allows to focus on those comorbidities that are prognostically more relevant in OSA. For example, the highest risk was associated with end-stage renal disease and aortic aneurysm, which showed the lowest prevalence in the sample . In addition, the higher the comorbidity score, the higher the mortality risk . Unfortunately, the impact of OSA treatment was not evaluated in detail.
Comorbidities and mortality in CPAP-treated OSA
Other studies on the prognostic impact of comorbidities in OSA patients examined the effects of CPAP treatment. In a large study from Denmark, negative predictors for survival were male gender, age ≥60 years, no CPAP treatment, prior comorbidity, and low educational level . Another study found that age and occurrence of comorbidities predicted mortality in OSA patients . In patients aged >50 years, protective effects of CPAP treatment were shown only in patients with comorbidities . In patients with moderate-severe obesity and OSA, treatment with CPAP or noninvasive ventilation was associated with fewer cardiovascular events only in patients with a high number of comorbidities . The protective effect of CPAP might be larger in males than females with OSA [14, 15]. Other observational studies reported a protective effect of CPAP treatment in elderly OSA patients, who usually show a high prevalence of cardiometabolic comorbidities [16, 17].
Therefore, occurrence of comorbidities could identify subgroups of OSA patients at high risk, who might show benefit from CPAP treatment. Several studies have tried to define clinical phenotypes of OSA, and a cluster of patients with few OSA symptoms but high comorbidity burden has been reported by most studies published so far; such a cluster at least partly overlaps with the cluster of elderly OSA patients . More recent analyses pointed to sleep fragmentation and hypoxia as risk factors for cardiovascular events or death, and regular CPAP use appeared to exert a protective effect .
Common comorbidities in OSA patients
A comprehensive review of all possible comorbidities associated with OSA is beyond the scope of this article. Only the most frequent diseases will be discussed, with special attention to the most recent publications.
Cardiovascular and cerebrovascular diseases
Many studies have examined the role of OSA as a pathogenetic factor in cardiovascular and cerebrovascular diseases, as well as the potential protective effects of CPAP treatment. OSA may increase cardiovascular risk through multiple intermediate mechanisms, such as intermittent hypoxia, high sympathetic nervous activity, systemic hypertension, endothelial cell dysfunction, oxidative stress, inflammation, and accelerated atherosclerosis . On the other hand, chronic intermittent hypoxia could also activate some protective mechanisms, for example through the development of coronary vessel collaterals in patients with ischemic heart disease [20, 21].
The best studied cardiovascular comorbidity in OSA is systemic hypertension . Respiratory events during sleep are associated with hypertensive peaks occurring at the end of apneas and hypopneas, increased mean nocturnal blood pressure, and increased variability of blood pressure . A dose-response relationship has been shown between OSA severity and blood pressure . OSA patients may show elevated blood pressure values during sleep only, or during sleep and wakefulness, making 24-hour monitoring of blood pressure highly advisable in the OSA population . Resistant hypertension, i.e. incomplete blood pressure control on three antihypertensive drugs, is also frequent in OSA patients.
Several studies assessed the potential benefit of CPAP treatment on blood pressure values, and meta-analyses demonstrated that on average blood pressure decreased by only a small amount during CPAP treatment. However, the therapeutic effect of CPAP on hypertension varied according to OSA severity, compliance to CPAP treatment, and baseline blood pressure values . OSA patients with resistant hypertension showed a quite large decrease in blood pressure during CPAP . Antihypertensive drugs, and diuretics in particular, may slightly decrease AHI in OSA . In general, pharmacological treatment to control hypertension is necessary in hypertensive OSA patients, given the small effects of CPAP on blood pressure [28, 29].
Cardiovascular events and/or death
Several studies have addressed the question of OSA and cardiovascular morbidity and mortality. The prospective cohort study by Marin and coworkers reported a high cardiovascular risk in patients with severe OSA, which was normalized by CPAP treatment . The results of observational studies confirmed the association of untreated OSA with overall and cardiovascular mortality . In patients undergoing percutaneous coronary intervention, OSA was associated with occurrence of cardiovascular events during follow up [32, 33].
Randomized controlled trials (RCTs) in OSA patients with known coronary artery or cerebrovascular disease were then designed to verify whether treatment of OSA in patients at high cardiovascular risk might exert a protective role. However, RCTs on the effects of CPAP in patients with known coronary or cerebrovascular disease failed to show any protective effect of CPAP treatment on cardiovascular risk . Current uncertainty is due to the discrepancy between data obtained from observational studies and RCTs . Different patients’ characteristics according to the type of study may explain the different results. In particular, only patients without excessive daytime sleepiness were included in long-term RCTs, since it would be unethical to withdraw treatment in symptomatic patients. It is known that compliance to CPAP treatment in non-sleepy patients is low, as underlined in a recent pro-con debate [36, 37]. Good compliance to CPAP, i.e. mean nightly use ≥ 4 hours, was associated with some protection, especially for occurrence of stroke .
Another area of current interest is whether OSA may modify the outcomes of acute coronary syndromes (ACS). OSA prevalence is high in patients with ACS, and severe OSA occurs in 25% of the patients . The ongoing ISAACC trial (Impact of Continuous Positive Airway Pressure on Patients with ACS and Nonsleepy OSA) will provide long-term data on the effects of treating OSA in this population .
Arrhythmias are frequent in OSA patients, especially atrial fibrillation (AF). A permissive role of OSA towards the arrhythmogenic mechanism of AF is suggested by the higher risk of recurrence of AF in patients with OSA compared to non-OSA subjects and by the protective effect of CPAP treatment [41, 42]. Conversely, the literature on ventricular arrhythmias is relatively scarce and heterogeneous, as pointed out by a recent review . Incidence of sudden cardiac death is increased at night in OSA according to some reports  while other studies found a uniform distribution over 24 hours . Studies in patients with implantable cardioverter-defibrillator devices (ICD) have reported a high frequency of nocturnal discharge in OSA compared to non-OSA patients  or patients with chronic heart failure and central apneas [47, 48].
Several studies reported an increased risk of stroke in snorers  and OSA patients . CPAP treatment may reduce the risk of stroke , but most studies have used a composite cardiovascular outcome including stroke, rather than reporting data for each type of events. Available RCTs on the effects of CPAP in patients with stroke and OSA are usually short-term, and the low acceptance of CPAP treatment in patients with OSA and previous stroke is an additional difficulty to be considered. A recent meta-analysis on RCTs in the latter population reported improvement in neurological function in CPAP users . More studies are necessary to evaluate the possible protective effects of CPAP on survival after stroke.
The relationship between OSA and metabolism is highly complex. On one hand, OSA is often associated with obesity, which by itself is characterized by disturbed energy metabolism and adipose tissue inflammation . On the other hand, nocturnal intermittent hypoxia has been shown to affect glucose metabolism, and OSA could independently contribute to the pathogenesis of metabolic disorders . The bidirectional relationships between OSA and disturbed energy metabolism  or type 2 diabetes  are current topics of interest, given the obesity epidemics and the increasing prevalence of type 2 diabetes worldwide.
OSA and the Metabolic Syndrome
The metabolic syndrome (MetS), a pre-diabetic state associated with central obesity and increased cardiovascular risk , is highly prevalent in OSA patients  and, according to some authors, OSA should be considered as an additional manifestation of MetS . OSA may play a role in the pathogenesis of insulin resistance, the main feature of MetS, through intermittent hypoxia [60, 61] and sleep loss or fragmentation [62, 63, 64]. A fascinating recent research area is represented by the role of gut microbiota in metabolic derangements induced by intermittent hypoxia [65, 66] or sleep fragmentation . Readers interested in the complex mechanisms of the interaction between OSA/intermittent hypoxia, adipocyte dysfunction, and inflammatory activation in adipose tissue, are referred to extensive reviews on these topics [68, 69, 70, 71].
Although a positive effect of OSA treatment on metabolic disturbances might be expected based on the pathophysiological links described above, CPAP treatment does not modify visceral fat or metabolic variables [72, 73] unless concurrent weight loss occurs . Nevertheless, short-term CPAP treatment for 8 hours/night improves insulin resistance, suggesting that prolonged nightly treatment with CPAP may be needed to modify glucose metabolism in OSA, possibly through decreased sympathetic activation . Activity of insulin in the carotid body, and a common pathway involving both intermittent hypoxia and metabolism, is an interesting recent pathogenetic hypothesis possibly explaining the intertwining effects of OSA and glucose dysmetabolism .
OSA and diabetes
The bidirectional relationship between OSA and diabetes is especially interesting from a clinical point of view . Treatment of OSA may help to prevent severe consequences of diabetes. This might indeed be the case, since although glycemic control does not improve during CPAP treatment according to meta-analyses [78, 79], untreated OSA in diabetic patients is associated with increased prevalence of neuropathy , peripheral arterial disease , diabetic retinopathy  and diabetic nephropathy [83, 84, 85]. Data on the effects of CPAP on diabetic complications are scarce. Compared to poorly compliant patients, optic nerve function improved in severe OSA patients with good compliance to CPAP treatment . A recent post-hoc analysis of data from the SAVE study highlighted a higher risk of adverse outcomes in diabetic compared to non-diabetic patients, and a protective effect of CPAP on recurrent cardiovascular events only in diabetic patients with OSA showing a good adherence to CPAP treatment, i.e. at least 4 h/night, in the first 2 years of the study .
In summary, OSA may worsen metabolic abnormalities, and OSA treatment with sufficient adherence could play a protective role, especially when concomitant lifestyle interventions and weight loss are implemented. Screening for OSA in diabetic patients should be systematically done, since CPAP treatment for at least 4 h/night may be protective, especially when diabetic complications are also present .
Renal diseases and OSA share common risk factors, like arterial hypertension, diabetes mellitus, obesity and advanced age. Each of such factors may give some independent contribution to the onset and progression of the other one . OSA may endanger the kidney through several interacting mechanisms, including nocturnal intermittent hypoxemia, recurrent nocturnal blood pressure peaks, sympathetic hyperactivity, hyperactivation of intrarenal renin-angiotensin system, oxidative stress and systemic inflammation, endothelial dysfunction. A relationship between nocturnal hypoxemia and hyperactivation of the intrarenal renin-angiotensin system has been experimentally demonstrated .
Cross-sectional epidemiological studies have not consistently reported an association between OSA and either albumin excretion or eGFR. When an association was found, either severity of nocturnal hypoxemia  or the apnea/hypopnea index  were reported to correlate to renal alterations. These studies highly differed in design, sample size, recruitment criteria (patients referred to sleep laboratories, general population, diabetes as an inclusion or an exclusion criterion), so that it is difficult to draw firm conclusions from them.
More interesting and consistent results were obtained from longitudinal investigations. In a large study on US veterans, the annual rate of decline of eGFR was higher among patients diagnosed with sleep apnea than among controls . Three retrospective cohort studies in Taiwan found a higher incidence of chronic kidney disease (any stage) among OSA than control subjects [94, 95, 96]. However, all these studies lacked polysomnographic information about OSA severity. Another longitudinal study on patients recruited in a sleep laboratory found that an accelerated decline in eGFR was more common among subjects who spent >12% of sleep time with oxygen saturation <90% than in less hypoxic subjects . By contrast, a long-term study on the population-based Wisconsin Sleep Cohort did not find any difference in the rate of decline of eGFR between subjects initially showing an AHI>15 and other subjects . However, the less severe nocturnal hypoxemia in sleep apnea subjects from the general population may at least partly explain the different results obtained in the Wisconsin cohort and in studies on OSA patients.
Most papers on the effects of OSA treatment on kidney function showed positive effects of CPAP. Two small studies on subjects with a high baseline GFR found a reduction of filtration fraction due to decrease in glomerular hyperfiltration [99, 100]. Two other small studies on subjects with mildly or severely impaired renal function observed an increase in eGFR  or a decrease in eGFR decline . More recently, a RCT could not demonstrate a difference in the rate of eGFR decline between subjects with OSA and cardiovascular diseases treated by CPAP or under “usual care”; however, the power of the study could be insufficient to demonstrate a difference between the two groups . In a study with a larger number of patients recruited in different sleep laboratories, therapy with fixed CPAP, but not with autoadjusting CPAP, could blunt the spontaneous trend of eGFR to decline over time .
In summary, there is some evidence that OSA may worsen kidney function through several mechanisms, and CPAP may exert beneficial effects.
Both OSA and chronic obstructive pulmonary disease (COPD) are common and may occur in the same patient. Their association is known as “overlap syndrome” since the early studies . Prevalence of the overlap syndrome has been reported at 1.0 to 3.6% in the general population, 8-56% in OSA patients, and 3-66% in COPD patients . In OSA patients, prevalence of the overlap syndrome was found to increase with age, in agreement with COPD being more prevalent in elderly than middle-aged subjects . In COPD patients, prevalence of respiratory events during sleep was high, with sleep disordered breathing (SDB) in 66% of patients with moderate to severe COPD . In COPD patients undergoing pulmonary rehabilitation an AHI≥15/h was found in 45% of the sample . COPD patients often show poor sleep quality [109, 110] and hypoventilation during sleep . Use of oxygen during sleep could contribute to diagnostic uncertainty regarding OSA . In addition, insufficient data are available on the role of either COPD or OSA severity on the clinical presentation or outcomes of the overlap syndrome, since the consequences of severe OSA associated with mild COPD may differ from those of mild OSA associated with severe COPD.
As outcomes are concerned, early studies reported lower PaO2 and higher PaCO2 in overlap patients compared to OSA patients with a similar AHI, associated with higher pulmonary artery pressure at rest and during exercise . More recent observational studies reported increased mortality in overlap patients compared to OSA patients [113, 114, 115], and a protective effect of CPAP treatment [113, 116, 117]. By contrast, a complex study in over 6,000 subjects from the general population recently reported that mortality was higher in patients with SDB defined as AHI≥5, but occurrence of SDB and SDB severity could mitigate the effects of decreasing FEV1 on mortality . These data suggest that OSA and COPD pathophysiology may interact, with low body mass index (BMI) and lung hyperinflation protecting against OSA in COPD, and upper airway and systemic inflammation in COPD potentiating the detrimental effects of OSA [119, 120]. Better phenotypic characterization of patients with overlap syndrome is needed, to optimize therapeutic strategies of both diseases.
Asthma and obstructive sleep apnea (OSA) are highly prevalent disorders which are often associated . OSA symptoms are frequent in asthmatic patients [122, 123, 124, 125, 126], who also report daytime sleepiness , poor asthma control [128, 129, 130, 131], and reduced quality of life . Longitudinal data from the Wisconsin Sleep Cohort suggested that asthma at baseline increased the risk to develop OSA during follow up .
Sleep studies confirmed that OSA is more common in asthmatics than in controls [134, 135, 136], and OSA resulted associated with a higher frequency of asthma exacerbations . Mild-moderate OSA occurred in 49% of patients with difficult-to-treat asthma . Patients with severe asthma showed increased apnea-hypopnea index (AHI), poor sleep quality and daytime sleepiness . However, lower airway resistance was shown to increase in asthmatic patients during slow wave sleep, whereas upper airway resistance remained low . Moreover, hypopneas rather than apneas were the main type of respiratory events recorded in asthmatic patients . On the other hand, upper airways in patients with OSA and asthma were shown to be smaller than in patients with either disease or controls, suggesting a synergistic role on upper airway inflammation played by both OSA and asthma .
In patients with suspected or confirmed OSA, some studies highlighted the association of asthma and obesity, especially in women [141, 142, 143]. In the European Sleep Apnea Database (ESADA), OSA and asthma were frequent in obese women . A community-based study in Uppsala reported worse sleep quality and occurrence of nocturnal hypoxemia in women with both OSA and asthma, who showed higher BMI compared to controls or women with either asthma or OSA . Other studies reported a positive relationship between severity of OSA and severity of asthma symptoms , higher prevalence of mild-moderate rather than severe OSA in patients with asthma [135, 143] or no relationship between asthma and OSA severity . In the ESADA cohort, the distribution of OSA severity was similar in patients with and without physician-diagnosed asthma, and unaffected by treatment for asthma or for gastroesophageal reflux . These differences in results among studies may at least partly reflect variable referral patterns for sleep studies in asthmatic patients, and further studies are needed to better define the real impact of OSA in asthma, and of asthma in OSA.
It is still uncertain whether treatment of OSA with continuous positive airway pressure (CPAP) might improve asthma control or pulmonary function. Some studies reported positive results [146, 147, 148] while other studies were negative [149, 150]. One study reported a decreased rate of FEV1 decline in asthmatic patients treated with CPAP , but the majority of studies agree on unchanged pulmonary function after CPAP. A recent systematic review pointed out that results of different studies do not allow to document a definite improvement in asthma control, although a positive effect of CPAP treatment seems to occur in patients with severe OSA or poorly controlled asthma .
In summary, the association of asthma and OSA would benefit from careful phenotyping of both diseases. Neutrophilic rather than eosinophilic inflammation was found in asthmatic patients with OSA [137, 152], suggesting a possible contribution of OSA to neutrophilic asthma. Further studies are needed to assess whether CPAP treatment could be a useful adjunct of asthma treatment in OSA patients, especially in cases of poorly controlled asthma.
The association of OSA and cancer has been explored in the last few years. In mice bearing human subcutaneous melanoma xenografts, intermittent hypoxia exposure accelerated tumor progression, and was associated with both metastases and resistance to treatment . Such an effect was possibly mediated by activation of the hypoxia inducible factor (HIF) 1-alpha pathway [153, 154].
Epidemiological and clinical studies have explored the association of OSA and cancer in humans. Cancer mortality during follow up was increased in OSA patients compared to controls in general population samples [155, 156], cohorts of OSA patients , and cohorts of cancer patients , in association with OSA severity and duration of nocturnal hypoxemia. Some studies however did not show increased mortality associated with occurrence of OSA in the general population  or cohorts of cancer patients [160, 161].
Other studies reported increased incidence of cancer in cohorts of OSA patients compared to controls [156, 159, 162, 163, 164, 165]; however, two population-based studies were negative [166, 167], but one study assessed only OSA symptoms rather than collecting objective sleep data . According to some reports, incidence of cancer was especially high in relatively young OSA patients [157, 162]. Two studies assessing different cancer localizations reported a high risk of pancreatic cancer and melanoma in OSA patients, whereas risk for colorectal cancer was relatively low compared to non-OSA subjects [159, 160]. Therefore, although most studies indicate that intermittent hypoxia in OSA may increase cancer risk, firm evidence is still lacking, as confirmed by results of two recent meta-analyses [168, 169].
A series of studies focused on the association of OSA and cutaneous malignant melanoma (CMM), to verify whether data from the mouse model could be confirmed in humans. Tumor aggressiveness was increased in CMM patients with OSA and long time spent at low oxygen saturation (CT90%) or high oxygen desaturation index (ODI 4%) [158, 170, 171, 172, 173]. Interestingly, tumor aggressiveness was positively associated with expression of the adhesion molecule VCAM-1 , HIF-1alpha , but not with expression of vascular endothelial growth factor (VEGF) . Similar results were reported in patients with lung cancer and OSA .
In summary, the association of OSA and cancer is biologically plausible, as shown by the experimental studies using the intermittent hypoxia model. Human data on incidence of cancer and mortality in OSA patients confirm experimental data, especially in cohorts of CMM patients. However, no definitive evidence is available, and further studies are required especially concerning the possible higher risk of cancer in young OSA patients. Moreover, no study has assessed the potentially protective role of CPAP treatment, and studies based on administrative data often lack adjustments for known risk factors for cancer.
Comorbidities are frequent in OSA patients, and OSA appears as a potential trigger for worse prognosis by worsening chronic organ damage , justifying the hypothesis of a dangerous liaison between OSA and comorbidities. Although the possible protective role of OSA treatment is still uncertain, it could differ among different clinical phenotypes of OSA patients. In that regard, studies are still moving their first steps [18, 175], but some data are available showing different responses depending on OSA phenotype . Such view is confirmed by the recent report developed by European experts on OSA, which suggests that both symptoms and organ damage should be considered when choosing the appropriate treatment for OSA . Although personalized medicine is slowly developing in the OSA field, testing a model similar to the model developed for COPD might provide useful hints on the possible detrimental role of comorbidities in OSA patients and suggest the best therapeutic approaches. Moreover, it is necessary to consider the role of comorbidities in elderly OSA patients and women with OSA, given the differences in pathophysiology and clinical presentation compared to the usual model of middle-aged men that dominates the current literature. Careful assessment of comorbidities should become standard clinical practice for OSA patients.
This work has been funded by University of Palermo, Italy, and Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy. Publication costs of this article will be funded by Novamedia and Italian Respiratory Society (IRS).
Availability of data and materials
MRB conceived the manuscript; PB, EM and AC contributed to reference search; all authors contributed in writing the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 2.Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension. 2003;42:1067–74. https://doi.org/10.1161/01.HYP.0000101686.98973.A3.CrossRefPubMedGoogle Scholar
- 4.Senaratna CV, English DR, Currier D, Perret JL, Lowe A, Lodge C, Russell M, Sahabandu S, Matheson MC, Hamilton GS, Dharmage SC. Sleep apnoea in Australian men: disease burden, co-morbidities, and correlates from the Australian longitudinal study on male health. BMC Public Health. 2016;16(Suppl 1):1029. https://doi.org/10.1186/s12889-016-3703-8.CrossRefPubMedGoogle Scholar
- 5.Appleton SL, Gill TK, Lang CJ, Taylor AW, McEvoy RD, Stocks NP, González-Chica DA, Adams RJ. Prevalence and comorbidity of sleep conditions in Australian adults: 2016 Sleep Health Foundation national survey. Sleep Health. 2018;4:13–9. https://doi.org/10.1016/j.sleh.2017.10.006.CrossRefPubMedGoogle Scholar
- 6.Tveit RL, Lehmann S, Bjorvatn B. Prevalence of several somatic diseases depends on the presence and severity of obstructive sleep apnea. PLoS ONE. 2018;13(2):e0192671. https://doi.org/10.1371/journal.pone.0192671.
- 7.Heinzer R, Marti-Soler H, Marques-Vidal P, Tobback N, Andries D, Waeber G, Preisig M, Vollenweider P, Haba-Rubio J. Impact of sex and menopausal status on the prevalence, clinical presentation, and comorbidities of sleep-disordered breathing. Sleep Med. 2018;51:29–36. https://doi.org/10.1016/j.sleep.2018.04.016.CrossRefPubMedGoogle Scholar
- 9.Ruel G, Martin SA, Lévesque JF, Wittert GA, Adams RJ, Appleton SL, Shi Z, Taylor AW. Association between multimorbidity and undiagnosed obstructive sleep apnea severity and their impact on quality of life in men over 40 years old. Glob Health Epidemiol Genom. 2018 Jun 4;3:e10. https://doi.org/10.1017/gheg.2018.9.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Jennum P, Tønnesen P, Ibsen R, Kjellberg J. All-cause mortality from obstructive sleep apnea in male and female patients with and without continuous positive airway pressure treatment: a registry study with 10 years of follow-up. Nat Sci Sleep. 2015;7:43–50. https://doi.org/10.2147/NSS.S75166.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Jennum P, Tønnesen P, Ibsen R, Kjellberg J. Obstructive sleep apnea: effect of comorbidities and positive airway pressure on all-cause mortality. Sleep Med. 2017;36:62–6. https://doi.org/10.1016/j.sleep.2017.04.018.
- 15.de Batlle J, Bertran S, Turino C, Escarrabill J, Sánchez-de-la-Torre M, Woehrle H, Barbé F. Mortality in patients treated with continuous positive airway pressure at the population level. Am J Respir Crit Care Med. 2018;197:1486–148. https://doi.org/10.1164/rccm.201709-1889LE.
- 16.López-Padilla D, Alonso-Moralejo R, Martínez-García MÁ, De la Torre CS. Díaz de Atauri MJ. Continuous positive airway pressure and survival of very elderly persons with moderate to severe obstructive sleep apnea. Sleep Med. 2016;19:23–9. https://doi.org/10.1016/j.sleep.2015.10.015.CrossRefPubMedGoogle Scholar
- 17.Ou Q, Chen Y-C, Zhuo S-Q, Tian X-T, He C-H, Lu X-L, Gao X-L. Continuous positive airway pressure treatment reduces mortality in elderly patients with moderate to severe obstructive severe sleep apnea: a cohort study. PLoS One. 2015;10(6):e0127775. https://doi.org/10.1371/journal.pone.0127775.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Bonsignore MR, Suarez Giron MC, Marrone O, Castrogiovanni A, Montserrat JM. Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment. Eur Respir Rev. 2017; 26(146). pii:170069, doi: https://doi.org/10.1183/16000617.0069-2017.
- 19.Zinchuk AV, Jeon S, Koo BB, Yan X, Bravata DM, Qin L, Selim BJ, Strohl KP, Redeker NS, Concato J, Yaggi HK. Polysomnographic phenotypes and their cardiovascular implications in obstructive sleep apnoea. Thorax. 2018;73:472–80. https://doi.org/10.1136/thoraxjnl-2017-210431.CrossRefPubMedGoogle Scholar
- 22.Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, Lévy P, Riha R, Bassetti C, Narkiewicz K, Mancia G, WT MN. EU COST Action B26 members. Recommendations for the management of patients with obstructive sleep apnoea and hypertension. Eur Respir J. 2013;41:523–38. https://doi.org/10.1183/09031936.00226711.CrossRefPubMedGoogle Scholar
- 25.Haentjens P, Van Meerhaeghe A, Moscariello A, De Weerdt S, Poppe K, Dupont A, Velkeniers B. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med. 2007;167:757–64.CrossRefGoogle Scholar
- 26.Iftikhar IH, Valentine CW, Bittencourt LR, Cohen DL, Fedson AC, Gíslason T, Penzel T, Phillips CL, Yu-sheng L, Pack AI, Magalang UJ. Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis. J Hypertens. 2014;32:2341–50. https://doi.org/10.1097/HJH.0000000000000372.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Khurshid K, Yabes J, Weiss PM, Dharia S, Brown L, Unruh M, Jhamb M. Effect of anti-hypertensive medications on the severity of obstructive sleep apnea: a systematic review and meta-analysis. J Clin Sleep Med. 2016;12:1143–51. https://doi.org/10.5664/jcsm.6054.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Revol B, Jullian-Desayes I, Bailly S, Regnaut L, Tamisier R, Pepin JL, Joyeux-Faure M. What is the best treatment strategy for obstructive sleep apnoea-related hypertension? Hypertens Res. 2018 Oct 15. https://doi.org/10.1038/s41440-018-0114-5.
- 32.Lee CH, Sethi R, Li R, Ho HH, Hein T, Jim MH, Loo G, Koo CY, Gao XF, Chandra S, Yang XX, Furlan SF, Ge Z, Mundhekar A, Zhang WW, Uchôa CH, Kharwar RB, Chan PF, Chen SL, Chan MY, Richards AM, Tan HC, Ong TH, Roldan G, Tai BC, Drager LF, Zhang JJ. Obstructive sleep apnea and cardiovascular events after percutaneous coronary intervention. Circulation. 2016;133:2008–17. https://doi.org/10.1161/CIRCULATIONAHA.115.019392.CrossRefPubMedGoogle Scholar
- 33.Wang X, Fan J-Y, Zhang Y, Nie S-P, Wei Y-X. Association of obstructive sleep apnea with cardiovascular outcomes after percutaneous coronary intervention. A systematic review and meta-analysis. Medicine. 2018;97(17(e0621)). https://doi.org/10.1097/MD.0000000000010621.
- 34.Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, Neal B. Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: a systematic review and meta-analysis. JAMA. 2017;318:156–66. https://doi.org/10.1001/jama.2017.7967.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S. INCOSACT Initiative (International Collaboration of Sleep Apnea Cardiovascular Trialists). Sleep apnea and cardiovascular disease: lessons from recent trials and need for team science. Circulation. 2017;136:1840–50. https://doi.org/10.1161/CIRCULATIONAHA.117.029400.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Martinez-Garcia MA, Campos-Rodriguez F, Javaheri S, Gozal D. Pro: continuous positive airway pressure and cardiovascular prevention. Eur Respir J. 2018; 51.pii: 1702400. doi: https://doi.org/10.1183/13993003.02400-2017.
- 37.McEvoy RD, Kohler M. Con: continuous positive airway pressure and cardiovascular prevention. Eur Respir J 2018; 51. pii: 1702721. doi: https://doi.org/10.1183/13993003.02721-2017.
- 38.Khan SU, Duran CA, Rahman H, Lekkala M, Saleem MA, Kaluski E. A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea. Eur Heart J. 2018;39:2291–7. https://doi.org/10.1093/eurheartj/ehx597.CrossRefPubMedGoogle Scholar
- 40.Esquinas C, Sánchez-de-la Torre M, Aldomá A, Florés M, Martínez M, Barceló A, Barbé F. Spanish Sleep Network. Rationale and methodology of the impact of continuous positive airway pressure on patients with ACS and nonsleepy OSA: the ISAACC Trial. Clin Cardiol. 2013;36:495–501. https://doi.org/10.1002/clc.22166.CrossRefPubMedGoogle Scholar
- 42.Congrete S, Bintvihok M, Thongprayoon C, Bathini T, Boonpheng B, Sharma K, Chokesuwattanaskul R, Srivali N, Tanawuttiwat T, Cheungpasitporn W. Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: A meta-analysis. J Evid Based Med. 2018;11:145–51. https://doi.org/10.1111/jebm.12313.CrossRefPubMedGoogle Scholar
- 44.Gami AS, Olson EJ, Shen WK, Wright RS, Ballman KV, Hodge DO, Herges RM, Howard DE, Somers VK. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol. 2013;62:610–6. https://doi.org/10.1016/j.jacc.2013.04.080.CrossRefPubMedGoogle Scholar
- 47.Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, Langer C, Horstkotte D, Oldenburg O. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J. 2011 Jan;32(1):61–74. https://doi.org/10.1093/eurheartj/ehq327.CrossRefPubMedGoogle Scholar
- 57.Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.CrossRefGoogle Scholar
- 59.Gaines J, Vgontzas AN, Fernandez-Mendoza J, Bixler EO. Obstructive sleep apnea and the metabolic syndrome: The road to clinically-meaningful phenotyping, improved prognosis, and personalized treatment. Sleep Med Rev. 2018;42:211–9. https://doi.org/10.1016/j.smrv.2018.08.009.CrossRefPubMedGoogle Scholar
- 60.Iiyori N, Alonso LC, Li J, Sanders MH, Garcia-Ocana A, O'Doherty RM, Polotsky VY, O'Donnell CP. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med. 2007;175:851–7. https://doi.org/10.1164/rccm.200610-1527OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 63.Hakim F, Wang Y, Carreras A, Hirotsu C, Zhang J, Peris E, Gozal D. Chronic sleep fragmentation during the sleep period induces hypothalamic endoplasmic reticulum stress and PTP1b-mediated leptin resistance in male mice. Sleep. 2015;38:31–40. https://doi.org/10.5665/sleep.4320.CrossRefPubMedPubMedCentralGoogle Scholar
- 64.Zou J, Xia Y, Xu H, Fu Y, Qian Y, Li X, Zhao X, Zou J, Meng L, Liu S, Zhu H, Yi H, Guan J, Chen B, Yin S. Independent relationships between cardinal features of obstructive sleep apnea and glycometabolism: a cross-sectional study. Metabolism. 2018;85:340–7. https://doi.org/10.1016/j.metabol.2017.11.021.CrossRefPubMedGoogle Scholar
- 65.Moreno-Indias I, Torres M, Montserrat JM, Sanchez-Alcoholado L, Cardona F, Tinahones FJ, Gozal D, Poroyko VA, Navajas D, Queipo-Ortuño MI, Farré R. Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur Respir J. 2015;45:1055–65. https://doi.org/10.1183/09031936.00184314.CrossRefPubMedGoogle Scholar
- 66.Tripathi A, Melnik AV, Xue J, Poulsen O, Meehan MJ, Humphrey G, Jiang L, Ackermann G, McDonald D, Zhou D, Knight R, Dorrestein PC, Haddad GG. Intermittent hypoxia and hypercapnia, a hallmark of obstructive sleep apnea, alters the gut microbiome and metabolome. mSystems. 2018; 3(3). pii: e00020-e00018. doi: https://doi.org/10.1128/mSystems.00020-18.
- 67.Poroyko VA, Carreras A, Khalyfa A, Khalyfa AA, Leone V, Peris E, Almendros I, Gileles-Hillel A, Qiao Z, Hubert N, Farré R, Chang EB, Gozal D. Chronic sleep disruption alters gut microbiota, induces systemic and adipose tissue inflammation and insulin resistance in mice. Sci Rep. 2016;6:35405. https://doi.org/10.1038/srep35405.CrossRefPubMedPubMedCentralGoogle Scholar
- 74.Chirinos JA, Gurubhagavatula I, Teff K, Rader DJ, Wadden TA, Townsend R, Foster GD, Maislin G, Saif H, Broderick P, Chittams J, Hanlon AL, Pack AI. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med. 2014;370:2265–75. https://doi.org/10.1056/NEJMoa1306187.CrossRefPubMedPubMedCentralGoogle Scholar
- 75.Pamidi S, Wroblewski K, Stepien M, Sharif-Sidi K, Kilkus J, Whitmore H, Tasali E. Eight hours of nightly continuous positive airway pressure treatment of obstructive sleep apnea improves glucose metabolism in patients with prediabetes. A randomized controlled trial. Am J Respir Crit Care Med. 2015;192:96–105. https://doi.org/10.1164/rccm.201408-1564OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 78.Zhu B, Ma C, Chaiard J, Shi C. Effect of continuous positive airway pressure on glucose metabolism in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Sleep Breath. 2018;22:287–95. https://doi.org/10.1007/s11325-017-1554-x.CrossRefPubMedGoogle Scholar
- 80.Tahrani AA, Ali A, Raymond NT, Begum S, Dubb K, Mughal S, Jose B, Piya MK, Barnett AH, Stevens MJ. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med. 2012;186:434–41. https://doi.org/10.1164/rccm.201112-2135OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 81.Stadler S, Jalili S, Schreib A, Jung B, Zeman F, Böger CA, Heid IM, Arzt M. DIACORE study group. Association of sleep-disordered breathing with severe chronic vascular disease in patients with type 2 diabetes. Sleep Med. 2018;48:53–60. https://doi.org/10.1016/j.sleep.2018.05.001.CrossRefPubMedGoogle Scholar
- 82.Altaf QA, Dodson P, Ali A, Raymond NT, Wharton H, Fellows H, Hampshire-Bancroft R, Shah M, Shepherd E, Miah J, Barnett AH, Tahrani AA. Obstructive sleep apnea and retinopathy in patients with type 2 diabetes. A longitudinal study. Am J Respir Crit Care Med. 2017;196:892–900. https://doi.org/10.1164/rccm.201701-0175OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 86.Liguori C, Placidi F, Palmieri MG, Izzi F, Ludovisi R, Mercuri NB, Pierantozzi M. Continuous positive airway pressure treatment may improve optic nerve function in obstructive sleep apnea: an electrophysiological study. J Clin Sleep Med. 2018;14:953–8. https://doi.org/10.5664/jcsm.7158.CrossRefPubMedPubMedCentralGoogle Scholar
- 88.Borel A-L, Tamisier R, Böhme P, Priou P, Avignon A, Benhamou P-Y, Hanaire H, Pépin J-L, Kessler L, Valensi P, Darmon P, Gagnadoux F. Obstructive sleep apnoea syndrome in patients living with diabetes: Which patients should be screened? Diabetes Metab. 2018. pii: S1262-3636(18)30163-0. doi.org/10.1016/j.diabet.2018.08.006
- 90.Zalucky AA, Nicholl DD, Hanly PJ, Poulin MJ, Turin TC, Walji S, Handley GB, Raneri JK, Sola DY, Ahmed SB. Nocturnal hypoxemia severity and renin-angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med. 2015;192:873–80. https://doi.org/10.1164/rccm.201502-0383OC.CrossRefPubMedGoogle Scholar
- 91.Marrone O, Battaglia S, Steiropoulos P, Basoglu OK, Kvamme JA, Ryan S, Pepin JL, Verbraecken J, Grote L, Hedner J, Bonsignore MR. ESADA study group. Chronic kidney disease in European patients with obstructive sleep apnea: the ESADA cohort study. J Sleep Res. 2016;25(6):739–45. https://doi.org/10.1111/jsr.12426.CrossRefPubMedGoogle Scholar
- 92.Adams RJ, Appleton SL, Vakulin A, Hanly PJ, McDonald SP, Martin SA, Lang CJ, Taylor AW, McEvoy RD, Antic NA, Catcheside PG, Vincent AD, Wittert GA. Chronic kidney disease and sleep apnea association of kidney disease with obstructive sleep apnea in a population study of men. Sleep. 2017;40(1). https://doi.org/10.1093/sleep/zsw015.
- 93.Molnar MZ, Mucsi I, Novak M, Szabo Z, Freire AX, Huch KM, Arah OA, Ma JZ, Lu JL, Sim JJ, Streja E, Kalantar-Zadeh K, Kovesdy CP. Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans. Thorax. 2015;70:888–95. https://doi.org/10.1136/thoraxjnl-2015-206970.CrossRefPubMedPubMedCentralGoogle Scholar
- 94.Lee YC, Hung SY, Wang HK, Lin CW, Wang HH, Chen SW, Chang MY, Ho LC, Chen YT, Liou HH, Tsai TC, Tseng SH, Wang WM, Lin SH, Chiou YY. Sleep apnea and the risk of chronic kidney disease: A nationwide population-based cohort study. Sleep. 2015;38:213–21. https://doi.org/10.5665/sleep.4400.CrossRefPubMedPubMedCentralGoogle Scholar
- 96.Lin YS, Liu PH, Lin SW, Chuang LP, Ho WJ, Chou YT, Juan KC, Lo MT, Chu PH, Chen NH. Simple obstructive sleep apnea patients without hypertension or diabetes accelerate kidney dysfunction: a population follow-up cohort study from Taiwan. Sleep Breath. 2017;21:85–91. https://doi.org/10.1007/s11325-016-1376-2.CrossRefPubMedGoogle Scholar
- 99.Kinebuchi S, Kazama JJ, Satoh M, Sakai K, Nakayama H, Yoshizawa H, Narita I, Suzuki E, Gejyo F. Short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnoea syndrome. Clin Sci (Lond). 2004 Sep;107(3):317–22.CrossRefGoogle Scholar
- 100.Nicholl DD, Hanly PJ, Poulin MJ, Handley GB, Hemmelgarn BR, Sola DY, Ahmed SB. Evaluation of continuous positive airway pressure therapy on renin-angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med. 2014;190:572–80. https://doi.org/10.1164/rccm.201403-0526OC.CrossRefPubMedGoogle Scholar
- 103.Loffler KA, Heeley E, Freed R, Anderson CS, Brockway B, Corbett A, Chang CL, Douglas JA, Ferrier K, Graham N, Hamilton GS, Hlavac M, McArdle N, McLachlan J, Mukherjee S, Naughton MT, Thien F, Young A, Grunstein RR, Palmer LJ, Woodman RJ, Hanly PJ. McEvoy RD; SAVE (Sleep Apnea Cardiovascular Endpoints) Investigators. Effect of obstructive sleep apnea treatment on renal function in patients with cardiovascular disease. Am J Respir Crit Care Med. 2017;196:1456–62. https://doi.org/10.1164/rccm.201703-0603OC.CrossRefPubMedGoogle Scholar
- 104.Marrone O, Cibella F, Pépin JL, Grote L, Verbraecken J, Saaresranta T, Kvamme JA, Basoglu OK, Lombardi C, McNicholas WT, Hedner J. Bonsignore MR; ESADA Network. Fixed but not autoadjusting positive airway pressure attenuates the time-dependent decline in glomerular filtration rate in patients with OSA. Chest. 2018;154(2):326–34. https://doi.org/10.1016/j.chest.2018.04.020.CrossRefPubMedGoogle Scholar
- 106.Shawon MS, Perret JL, Senaratna CV, Lodge C, Hamilton GS, Dharmage SC. Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep apnea and chronic obstructive pulmonary disease: A systematic review. Sleep Med Rev. 2017 Apr;32:58–68. https://doi.org/10.1016/j.smrv.2016.02.007.CrossRefPubMedGoogle Scholar
- 107.Soler X, Gaio E, Powell FL, Ramsdell JW, Loredo JS, Malhotra A, Ries AL. High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2015 Aug;12(8):1219–25. https://doi.org/10.1513/AnnalsATS.201407-336OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 108.Schreiber A, Cemmi F, Ambrosino N, Ceriana P, Lastoria C, Carlucci A. Prevalence and predictors of obstructive sleep apnea in patients with chronic obstructive pulmonary disease undergoing inpatient pulmonary rehabilitation. COPD. 2018 Sep;21:1–6. https://doi.org/10.1080/15412555.2018.1500533.CrossRefGoogle Scholar
- 110.Geiger-Brown J, Lindberg S, Krachman S, McEvoy CE, Criner GJ, Connett JE, Albert RK, Scharf SM. Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:389–97. https://doi.org/10.2147/COPD.S75840.CrossRefPubMedPubMedCentralGoogle Scholar
- 114.Kendzerska T, Leung RS, Aaron SD, Ayas N, Sandoz JS, Gershon AS. Canadian Respiratory Research Network. Cardiovascular outcomes and all-cause mortality in patients with obstructive sleep apnea and chronic obstructive pulmonary disease (overlap syndrome). Ann Am Thorac Soc. 2018. https://doi.org/10.1513/AnnalsATS.201802-136OC.
- 115.Du W, Liu J, Zhou J, Ye D, OuYang Y, Deng Q. Obstructive sleep apnea, COPD, the overlap syndrome, and mortality: results from the 2005-2008 National Health and Nutrition Examination Survey. Int J Chron Obstruct Pulmon Dis. 2018;13:665–74. https://doi.org/10.2147/COPD.S148735.CrossRefPubMedPubMedCentralGoogle Scholar
- 116.Machado MC, Vollmer WM, Togeiro SM, Bilderback AL, Oliveira MV, Leitão FS, Queiroga F Jr, Lorenzi-Filho G, Krishnan JA. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J. 2010;35:132–7. https://doi.org/10.1183/09031936.00192008.CrossRefPubMedGoogle Scholar
- 118.Putcha N, Crainiceanu C, Norato G, Samet J, Quan SF, Gottlieb DJ, Redline S, Punjabi NM. Influence of lung function and sleep-disordered breathing on all-cause mortality. A community-based study. Am J Respir Crit Care Med. 2016;194:1007–14. https://doi.org/10.1164/rccm.201511-2178OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 123.Teodorescu M, Consens FB, Bria WF, Coffey MJ, McMorris MS, Weatherwax KJ, Palmisano J, Senger CM, Ye Y, Kalbfleisch JD, Chervin RD. Predictors of habitual snoring and obstructive sleep apnea risk in patients with asthma. Chest. 2009;135:1125–32. https://doi.org/10.1378/chest.08-1273.CrossRefPubMedGoogle Scholar
- 124.Emilsson ÖI, Bengtsson A, Franklin KA, Torén K, Benediktsdóttir B, Farkhooy A, Weyler J, Dom S, De Backer W, Gislason T, Janson C. Nocturnal gastro-oesophageal reflux, asthma and symptoms of OSA: a longitudinal, general population study. Eur Respir J. 2013;41:1347–54. https://doi.org/10.1183/09031936.00052512.CrossRefPubMedGoogle Scholar
- 125.Shen TC, Lin CL, Wei CC, Chen CH, Tu CY, Hsia TC, Shih CM, Hsu WH, Sung FC, Kao CH. Risk of obstructive sleep apnea in adult patients with asthma: a population-based cohort study in Taiwan. PLoS One. 2015;10:e0128461. https://doi.org/10.1371/journal.pone.0128461.CrossRefPubMedPubMedCentralGoogle Scholar
- 129.Dixon AE, Pratley RE, Forgione PM, Kaminsky DA, Whittaker-Leclair LA, Griffes LA, Garudathri J, Raymond D, Poynter ME, Bunn JY, Irvin CG. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011;128:508–15. https://doi.org/10.1016/j.jaci.2011.06.009.CrossRefPubMedPubMedCentralGoogle Scholar
- 130.Luyster FS, Teodorescu M, Bleecker E, Busse W, Calhoun W, Castro M, Chung KF, Erzurum S, Israel E, Strollo PJ, Wenzel SE. Sleep quality and asthma control and quality of life in non-severe and severe asthma. Sleep Breath. 2012;16:1129–37. https://doi.org/10.1007/s11325-011-0616-8.CrossRefPubMedGoogle Scholar
- 137.Taillé C, Rouvel-Tallec A, Stoica M, Danel C, Dehoux M, Marin-Esteban V, Pretolani M, Aubier M, d'Ortho MP. Obstructive sleep apnoea modulates airway inflammation and remodelling in severe asthma. PLoS One. 2016;11:e0150042. https://doi.org/10.1371/journal.pone.0150042.CrossRefPubMedPubMedCentralGoogle Scholar
- 140.Dultra FKAA, Tavares A, Dultra JA, Salles C, Crusoé-Rebelo IM, Barbosa I, Souza-Machado A. Pharyngeal airspace of asthmatic individuals and those suffering from obstructive sleep apnea syndrome: Study by CBCT. Eur J Radiol. 2017;95:342–8. https://doi.org/10.1016/j.ejrad.2017.09.002.CrossRefPubMedGoogle Scholar
- 144.Bonsignore MR, Pepin JL, Anttalainen U, Schiza SE, Basoglu OK, Pataka A, Steiropoulos P, Dogas Z, Grote L, Hedner J, McNicholas WT, Marrone O, ESADA Study Group. Clinical presentation of patients with suspected obstructive sleep apnea and self-reported physician-diagnosed asthma in the ESADA cohort. J Sleep Res. 2018:e12729. https://doi.org/10.1111/jsr.12729.
- 151.Davies SE, Bishopp A, Wharton S, Turner AM, Mansur AH. Does Continuous Positive Airway Pressure (CPAP) treatment of obstructive sleep apnoea (OSA) improve asthma-related clinical outcomes in patients with co-existing conditions? A systematic review. Respir Med. 2018;143:18–30. https://doi.org/10.1016/j.rmed.2018.08.004.CrossRefPubMedGoogle Scholar
- 152.Teodorescu M, Broytman O, Curran-Everett D, Sorkness RL, Crisafi G, Bleecker ER, Erzurum S, Gaston BM, Wenzel SE, Jarjour NN. National Institutes of Health, National Heart, Lung and Blood Institute Severe Asthma Research Program (SARP) Investigators. Obstructive Sleep Apnea Risk, Asthma Burden, and Lower Airway Inflammation in Adults in the Severe Asthma Research Program (SARP) II. J Allergy Clin Immunol Pract. 2015;3:566–575.e1. https://doi.org/10.1016/j.jaip.2015.04.002.CrossRefPubMedGoogle Scholar
- 154.Yoon DW, So D, Min S, Kim J, Lee M, Khalmuratova R, Cho CH, Park JW, Shin HW. Accelerated tumor growth under intermittent hypoxia is associated with hypoxia-inducible factor-1-dependent adaptive responses to hypoxia. Oncotarget. 2017;8(37):61592-61603. doi: 10.18632/oncotarget.18644.Google Scholar
- 156.Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J Clin Sleep Med. 2014;10:355–62. https://doi.org/10.5664/jcsm.3600.CrossRefPubMedPubMedCentralGoogle Scholar
- 157.Martínez-García MA, Campos-Rodriguez F, Durán-Cantolla J, de la Peña M, Masdeu MJ, González M, Del Campo F, Serra PC, Valero-Sánchez I, Ferrer MJ, Marín JM, Barbé F, Martínez M, Farré R, Montserrat JM. Spanish Sleep Network. Obstructive sleep apnea is associated with cancer mortality in younger patients. Sleep Med. 2014;15:742–8. https://doi.org/10.1016/j.sleep.2014.01.020.CrossRefPubMedGoogle Scholar
- 158.Li L, Lu J, Xue W, Wang L, Zhai Y, Fan Z, Wu G, Fan F, Li J, Zhang C, Zhang Y, Zhao J. Target of obstructive sleep apnea syndrome merge lung cancer: based on big data platform. Oncotarget. 2017;8: 21567-21578. doi:10.18632/oncotarget.15372.Google Scholar
- 160.Vilaseca A, Nguyen DP, Vertosick EA, Corradi RB, Musquera M, Pérez M, Fossati N, Sjoberg DD, Farré R, Almendros I, Montserrat JM, Benfante NE, Hakimi AA, Skanderup AJ, Russo P, Alcaraz A, Touijer KA. Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. World J Urol. 2017;35(1):51–6. https://doi.org/10.1007/s00345-016-1830-6.CrossRefPubMedGoogle Scholar
- 161.Dal Molin M, Brant A, Blackford AL, Griffin JF, Shindo K, Barkley T, Rezaee N, Hruban RH, Wolfgang CL, Goggins M. Obstructive sleep apnea and pathological characteristics of resected pancreatic ductal adenocarcinoma. PLoS One. 2016;11:e0164195. https://doi.org/10.1371/journal.pone.0164195.CrossRefPubMedPubMedCentralGoogle Scholar
- 162.Campos-Rodriguez F, Martinez-Garcia MA, Martinez M, Duran-Cantolla J, Peña Mde L, Masdeu MJ, Gonzalez M. Campo Fd, Gallego I, Marin JM, Barbe F, Montserrat JM, Farre R; Spanish Sleep Network. Association between obstructive sleep apnea and cancer incidence in a large multicenter Spanish cohort. Am J Respir Crit Care Med. 2013;187:99–105. https://doi.org/10.1164/rccm.201209-1671OC.CrossRefPubMedGoogle Scholar
- 169.Zhang XB, Peng LH, Lyu Z, Jiang XT, Du YP. Obstructive sleep apnoea and the incidence and mortality of cancer: a meta-analysis. Eur J Cancer Care (Engl). 2017;26. https://doi.org/10.1111/ecc.12427.
- 170.Martínez-García MÁ, Martorell-Calatayud A, Nagore E, Valero I, Selma MJ, Chiner E, Landete P, Montserrat JM, Carrera C, Pérez-Gil A, Campos-Rodríguez F, Farré R. Association between sleep disordered breathing and aggressiveness markers of malignant cutaneous melanoma. Eur Respir J. 2014;43:1661–8. https://doi.org/10.1183/09031936.00115413.CrossRefPubMedGoogle Scholar
- 171.Martínez-García MÁ, Riveiro-Falkenbach E, Rodríguez-Peralto JL, Nagore E, Martorell-Calatayud A, Campos-Rodríguez F, Farré R, Hernández Blasco L, Bañuls Roca J, Chiner Vives E, Sánchez-de-la-Torre A, Abad Capa J, Montserrat JM, Almendros I, Pérez-Gil A, Cabriada Nuño V, Cano-Pumarega I, Corral Peñafiel J, Diaz Cambriles T, Mediano O, Dalmau Arias J, Gozal D. Spanish Sleep Network. A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1α and VEGF expressions. Melanoma Res. 2017;27:558–64. https://doi.org/10.1097/CMR.0000000000000393.CrossRefPubMedGoogle Scholar
- 172.Santamaria-Martos F, Benítez I, Girón C, Barbé F, Martínez-García MA, Hernández L, Montserrat JM, Nagore E, Martorell A, Campos-Rodriguez F, Corral J, Cabriada V, Abad J, Mediano O, Troncoso MF, Cano-Pumarega I, Fortuna Gutierrez AM, Diaz-Cambriles T, Somoza-Gonzalez M, Almendros I, Farre R, Gozal D, Sánchez-de-la-Torre M; Spanish Sleep Network. Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea. Eur Respir J. 2018; 51(3). pii: 1701885. doi: https://doi.org/10.1183/13993003.01885-2017.
- 173.Almendros I, Martínez-García MÁ, Campos-Rodríguez F, Riveiro-Falkenbach E, Rodríguez-Peralto JL, Nagore E, Martorell-Calatayud A, Hernández Blasco L, Bañuls Roca J, Chiner Vives E, Sánchez-de-la-Torre A, Abad-Capa J, Montserrat JM, Pérez-Gil A, Cabriada-Nuño V, Cano-Pumarega I, Corral-Peñafiel J, Diaz-Cambriles T, Mediano O, Dalmau-Arias J, Farré R, Gozal D. Spanish Sleep Network. Intermittent hypoxia is associated with high hypoxia inducible factor-1α but not high vascular endothelial growth factor cell expression in tumors of cutaneous melanoma patients. Front Neurol. 2018;9:272. https://doi.org/10.3389/fneur.2018.00272.CrossRefPubMedPubMedCentralGoogle Scholar
- 174.Randerath W, Bassetti CL, Bonsignore MR, Farre R, Ferini-Strambi L, Grote L, Hedner J, Kohler M, Martinez-Garcia M, Mihaicuta S, Montserrat J, Pepin JL, Pevernagie D, Pizza F, Polo O, Riha R, Ryan S, Verbraecken J, McNicholas WT. Challenges and perspectives in obstructive sleep apnoea: Report by an ad hoc working group of the Sleep Disordered Breathing Group of the European Respiratory Society and the European Sleep Research Society. Eur Respir J. 2018. https://doi.org/10.1183/13993003.02616-2017.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.